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hat Can Human Genetics
each Us About the Causes
f Cardiovascular Disease?*
hristopher Newton-Cheh, MD, MPH,†‡
. Gustav Smith, MD‡§
oston and Cambridge, Massachusetts;
nd Lund, Sweden
enetic association studies have recently identified many
enetic variants that are common in the general population
nd associated with prevalent cardiovascular diseases and
raits. The effects of such variants are often quite modest,
ith odds ratios of 1.5 for risk alleles. Individually, these
ariants typically explain little of the population variation in
isease risk, although in aggregate they might explain as
uch as 5% to 15% of variation and thus could potentially
ave a role in clinical risk prediction. Variants with much
arger effects have also been identified from family-based
tudies, but each is typically private to the family in which it
rises, and hence very rare at the population level.
See page 2833
Even if the modest effect of a given variant turns out to be
f no value for risk prediction, its implication of a gene
reviously unrecognized to influence a trait can open new
venues for basic investigation and potentially novel therapeu-
ics. For example, the minor allele of the single nucleotide
olymorphism (SNP) rs3846663 has been associated with a
rivial 2.5-mg/dl higher low-density lipoprotein cholesterol
LDL-C) in a genome-wide association study (1). If one did
ot already know that 3-hydroxy-3-methylglutaryl-coenzyme
reductase is a rate-limiting enzyme in cholesterol synthesis
inhibited by statins), then finding this SNP in an intron of the
MGCR gene could allow identification of this “novel” target
or cholesterol-lowering therapy.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiovascular Research Center and Center for Human Genetic
esearch, Massachusetts General Hospital, Harvard Medical School, Boston, Mas-
achusetts; ‡Program in Medical and Population Genetics, Broad Institute of Harvard
nd Massachusetts Institute of Technology, Cambridge, Massachusetts; and theH
Department of Cardiology, Lund University, Lund, Sweden. Dr. Newton-Cheh is
n the scientific advisory board for hypertension and heart failure at Merck.There is yet another use to which genetic associations can
e put, namely to rule in or out the involvement of a clinical
rait as a causal factor in the development of disease.
bservational studies can identify a factor associated with
linical outcomes but cannot establish whether the factor is
ausal. For example, the presence of yellow fingers (found in
igarette smokers) might be associated with lung cancer or
ncreased LDL-C with ischemic heart disease. Abrogation
f the effect with adjustment for potential environmental
onfounders such as cigarette use suggests a noncausal
elationship, whereas robustness increases the likelihood of
causal connection. However, establishment of a causal
elation generally requires an interventional trial, such as
esting the ability of coloring fingers to reduce lung cancer
isk or of administering statins to lower cardiovascular risk.
bviously, this is only possible for modifiable causal risk
actors, and clinical trials are expensive, lengthy, and might
rove hazardous to the individuals undergoing intervention.
hat we can now identify genetic variants that impact
ommon, complex traits (e.g., LDL-C) and diseases (e.g.,
yocardial infarction) provides us with an alternate means
o test for causality. Central to this concept, termed Men-
elian randomization, is that genetic variants are randomly
ssigned at gametogenesis, following the laws of inheritance
s described by Gregor Mendel, and hence are not influ-
nced by other traits under study (2). Thus, we can use
enotype as an instrumental variable, not subject to con-
ounding, to elucidate the relationship between 2 associated
ariables.
First, the effect of genotype on a putative causal trait such
s yellow fingers or LDL-C is estimated. Next, the effect of
he putative causal trait on the outcome such as lung cancer
r coronary heart disease (CHD) is estimated. With these 2
stimates in hand, one can calculate the expected risk of
isease conferred by genotype under the model in which the
ntermediate factor lies in the causal pathway. Finally, the
ctual effect of genotype on the outcome variable is deter-
ined. If no association is observed in a sufficiently powered
ample, it might then be concluded that a causal association
etween yellow fingers and lung cancer is unlikely. Contrast
n imaginary SNP that causes yellow skin color to a SNP
ear genes encoding nicotinic acid receptors that influences
obacco use and risk of lung cancer (3).
Another example involves a recent report that examined
he relationship of the G allele of rs7553007, a SNP in the
RP gene, which is reproducibly associated with higher
-reactive protein (CRP). In approximately 28,000 CHD
ases compared with approximately 100,000 control sub-
ects, the same allele was not associated with higher cardio-
ascular risk, arguing against the direct causal relationship
etween CRP and CHD that has previously been proposed
4). One concern of negative Mendelian randomization
tudies is the statistical power to exclude an effect; the large
ample sizes examined in the CRP study allay such fears.
owever, such studies as the CRP study cannot exclude a
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Mendelian Randomization June 22, 2010:2843–5eaker causal effect of CRP on ischemic heart disease, for
hich even larger studies would be needed.
In the same study, despite a strong association with
igher CRP of the major A allele of SNP rs4420638 at the
POE gene, this allele was associated with lower CHD risk,
finding most consistent with the known strong association
f the allele with decreased LDL-C (4,5). This example
ighlights one of the potential pitfalls of Mendelian ran-
omization approaches: genetic variation might be associ-
ted with pleiotropic effects that can lead to the false
nference that an intermediate factor is causal as well as to
he false rejection of causality.
The Mendelian randomization approach has also been
pplied to several other risk factors for cardiovascular
isease, including positive results for LDL-C (6,7), lipopro-
ein(a) [Lp(a)] (8,9), and natriuretic peptides (10) and
egative results for fibrinogen (11), homocysteine (12), and
igh-density lipoprotein cholesterol (13,14). The latter 2
esults mirror negative clinical trials of vitamin supplemen-
ation (15) and cholesteryl ester transfer protein inhibition
16), respectively.
The causal relationship of LDL-C to cardiovascular risk
s well-supported by the continuous, graded relationship of
DL-C with CHD risk in observational studies, the exis-
ence of Mendelian syndromes such as familial hypercho-
esterolemia with increased risk of CHD, and the consistent
ffect of pharmacologic LDL-C–lowering on CHD risk. If
ne still did not believe that LDL-C is a causal factor
nfluencing CHD, a report in this issue of the Journal could
elp convince the persistent skeptic (17).
Benn et al. (17) studied the amino acid altering R46L
NP (rs11591147) of the proprotein convertase subtilisin/
exin type 9 (PCSK9) gene. The L allele of this SNP has
reviously been associated with decreased LDL-C levels
nd decreased risk of CHD, as first reported by Cohen et al.
6) and later replicated by the Myocardial Infarction Ge-
etics Consortium (18). Furthermore, rare gain-of-function
ariants in PCSK9 have been found to cause familial
ypercholesterolemia and increased risk of myocardial in-
arction. The minor 46L allele is relatively uncommon, with
frequency of approximately 1% to 3% in populations of
uropean descent, but exerts a large effect on LDL-C, with
reduction of 9% to 16% in heterozygotes (0.35 to 0.57
mol/l). Benn et al. (17) performed a Mendelian random-
zation study in 3 large samples from Denmark for a total
ample size of 1,204 46L carriers and 45,699 noncarriers.
hey observed 0.43 mmol/l (13%) lower LDL-C in het-
rozygotes and an odds ratio (OR) of 0.70 (95% confidence
nterval: 0.58 to 0.86) for CHD, which is lower than the
redicted OR of 0.95. Added to previous studies through
eta-analysis, an overall reduction in LDL-C of 0.43
mol/l (12%) and an OR of 0.72 (95% confidence interval:
.62 to 0.84) for CHD were observed.
The stronger genetic effect compared with that predicted
rom each limb of a SNP-to-low-density lipoprotein (LDL)
nd LDL-to-CHD model could reflect, as suggested by henn et al. (17) as well as others, the impact of lifelong
xposure to genetically-determined lower LDL-C levels by
ontrast to the shorter time horizon of estimates from
pidemiologic studies. In addition, imprecision in measure-
ent and trait changes over time can lead to underestima-
ion of each limb of the putative causal pathway and could
esult in a spurious mismatch between predicted and ob-
erved effects. Accordingly, Benn et al. (17) used regression
ilution adjustment, on the basis of correlation of repeated
easurements of LDL-C, to adjust the predicted effect.
As the authors point out, the discrepancy could also result
rom non-LDL mechanisms, in a fashion similar to the
elationship of the APOE SNP to both CRP and LDL-C.
he very specification of the intermediate phenotype could
lso be an alternative explanation. LDL-C is typically
although not in the current report) measured in the fasting
tate to allow its more accurate estimation from total and
igh-density lipoprotein cholesterol measurements and to
void acute effects of variability in dietary intake of fat and
holesterol. However, we spend only a portion of our lives in
he fasting state, and it is presumably not only fasting
DL-C that contributes to atherosclerosis. If genetic vari-
nts are identical in their effect on fasting LDL-C but
ariable in their effect on nonfasting LDL-C, then effects on
ardiovascular disease could be quite different than pre-
icted on the basis of the fasting LDL-C effect. Could the
tronger effect of the PCSK9 variant on CHD then be an
ffect of its “day-long” exposure to altered LDL-C as well as
he “lifelong” effect? Ultimately, refinement of phenotype to
ost closely capture the pathophysiology of human disease
s a central aim of medicine.
Obviously, Mendelian randomization studies could never
e the sole motivation for drug treatment. Clinical trials
ust always be the guide, given the previously described
imitations and the possibility of off-target toxicity and other
leiotropic effects and the constant risk that our models of
uman disease are incomplete. Genetic studies can, how-
ver, be a powerful means to identify and prioritize potential
herapeutic targets.
So what can we conclude at the moment regarding causal
isk factors for CHD from such experiments? The present
vidence indicates that, whereas CRP, homocysteine, and
brinogen are secure as risk factors for CHD, they seem
ore like yellow fingers: noncausal but integrated markers
f underlying vascular disease or inflammation (19). The
urrent report by Benn et al. (17) and a wealth of prior
bservational and interventional studies support the role of
DL-C as a causal and modifiable risk factor for CHD.
volving evidence supports a causal role for Lp(a), although
tudies of interventions that isolate Lp(a) effects are lacking.
nterpretation of future Mendelian randomization studies
ill need to consider the strengths and weaknesses of the
pproach, but there is clearly much to be learned from
uman genetics.
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